Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Epstein

Showing results (1071-1080 of 1,132) with videos related to

Pageof 114
Sort By:
The Journal of Urology|March 3, 2009
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2009
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
The American Journal of Surgical Pathology|July 16, 2014
Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conferenceMahul B Amin, Jonathan I Epstein, Thomas M Ulbright, et al.
American Journal of Clinical Pathology|February 27, 2024
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancersOleksandr N Kryvenko, Jonathan I Epstein, Ali Merhe, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
The American Journal of Pathology|October 29, 2022
Genomic Characterization of Prostatic Basal Cell CarcinomaJin-Yih Low, Minjeong Ko, Brian Hanratty, et al.
Human Pathology|February 15, 2001
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologistsW C Allsbrook, K A Mangold, M H Johnson, et al.
American Journal of Clinical Pathology|January 29, 2013
A broad survey of cathepsin K immunoreactivity in human neoplasmsGang Zheng, Guido Martignoni, Cristina Antonescu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2017
MSH2 Loss in Primary Prostate CancerLiana B Guedes, Emmanuel S Antonarakis, Michael T Schweizer, et al.
Human Pathology|April 26, 2017
Pericytic tumors of the kidney-a clinicopathologic analysis of 17 casesDeepika Sirohi, Steven C Smith, Jonathan I Epstein, et al.
Pageof 114

Showing results (1071-1080 of 1,132) with videos related to

Sort By:
Pageof 114
The Journal of Urology|March 3, 2009
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2009
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
The American Journal of Surgical Pathology|July 16, 2014
Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conferenceMahul B Amin, Jonathan I Epstein, Thomas M Ulbright, et al.
American Journal of Clinical Pathology|February 27, 2024
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancersOleksandr N Kryvenko, Jonathan I Epstein, Ali Merhe, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
The American Journal of Pathology|October 29, 2022
Genomic Characterization of Prostatic Basal Cell CarcinomaJin-Yih Low, Minjeong Ko, Brian Hanratty, et al.
Human Pathology|February 15, 2001
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologistsW C Allsbrook, K A Mangold, M H Johnson, et al.
American Journal of Clinical Pathology|January 29, 2013
A broad survey of cathepsin K immunoreactivity in human neoplasmsGang Zheng, Guido Martignoni, Cristina Antonescu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2017
MSH2 Loss in Primary Prostate CancerLiana B Guedes, Emmanuel S Antonarakis, Michael T Schweizer, et al.
Human Pathology|April 26, 2017
Pericytic tumors of the kidney-a clinicopathologic analysis of 17 casesDeepika Sirohi, Steven C Smith, Jonathan I Epstein, et al.
Pageof 114